基于核苷(酸)脂材的核酸药物纳米制剂体系研究进展

doi:10.16288/j.yczz.24-378

[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2025, Vol. 47 ›› Issue (8): 823-841.doi: 10.16288/j.yczz.24-378

• Review • Previous Articles Next Articles

Progress on nucleos(t)idyl lipid-based nanoparticles for nucleic acid drugs delivery

Jiamei Hong(), Hongyi Liu(), Hua Guo, Jing Yu, Qi Zhang, Zhu Guan, Zhenjun Yang()

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Received:2025-02-19 Revised:2025-05-08 Online:2025-05-09 Published:2025-05-09
Contact: Zhenjun Yang E-mail:m17802277004@163.com;hongyiliu@stu.pku.edu.cn;yangzj@bjmu.edu.cn
Supported by:
Beijing Science and Technology Commission Beijing Science and Technology Plan Project(Z231100004823026)

Abstract

Abstract:

Nucleic acid drugs can function at the gene level, and have the advantages of simple synthesis, easy modification and high specificity. However, there are many obstacles in transfection and in vivo delivery due to their negative charge, high molecular weight, and hydrophilicity. Lipid nanoparticles (LNPs) can encapsulate siRNA or mRNA through electrostatic interactions and five related drugs have been approved as of April 2025. However, due to the inevitable immunogenicity and hepatosplenic toxicity, most LNP-encapsulated nucleic acid drugs were terminated in the early clinical stage. Nucleos(t)idyl lipids are a class of amphiphilic molecules composed of nucleobases or nucleos(t)idyl heads, linkers and lipid tail chains, which can bind with the bases of nucleic acid drugs through hydrogen bonding and π-π stacking and self-assemble to form nanoparticles or micelles with broad application prospects. In this review, we summarize the research progress in delivery systems of nucleic acid drugs based on nucleos(t)idyl lipids and peptidyl lipids, and discuss their differences with LNP-encapsulated nucleic acid drugs, including structural characterization, molecular dynamics simulation, in vivo distribution, as well as efficacy and safety, so as to provide new ideas for improving the targeting delivery of nucleic acid drugs.

Key words: nucleic acid drugs, nucleos(t)idyl lipids, lipid nanoparticles, in vivo delivery

Jiamei Hong, Hongyi Liu, Hua Guo, Jing Yu, Qi Zhang, Zhu Guan, Zhenjun Yang. Progress on nucleos(t)idyl lipid-based nanoparticles for nucleic acid drugs delivery[J]. Hereditas(Beijing), 2025, 47(8): 823-841.

Figures/Tables 11

Table 1

The approved nucleic acid drugs"

种类	上市年份	通用名/ 商品名	适应症	给药方式	包载/缀合	修饰	研发公司
反义核酸	1998	Fomivirsen/ Vitraveve	巨细胞病毒性视网膜炎	玻璃体注射	Naked	PS	Ionis Pharmaceuticals (美国)
	2013	Mipomersen/ Kynamro	纯合子家族性高胆固醇血症	皮下注射	Naked	PS, 2′-OMOE	Ionis Pharmaceuticals (美国)
	2016	Eteplirsen/ Exongys 51	杜氏肌营养不良症	静脉注射	Naked	PMO	Sarepta Therapeutics (美国)
	2016	Nusinersen/ Spinraza	脊髓性肌萎缩症	鞘内注射	Naked	PS, 2′-OMOE	Ionis Pharmaceuticals (美国)/ Biogen (美国)
	2018	Inotersen/ Tegsedi	成人遗传性转甲状腺素蛋白淀粉样变性	皮下注射	Naked	PS, 2′-OMOE	Ionis Pharmaceuticals (美国)/ Akcea Therapeutics (美国)
	2019	Golodirsen/ Vyondys 53	杜氏肌营养不良症	静脉注射	Naked	PMO	Sarepta Therapeutics (美国)
	2019	Volanesorsen/ Waylivra	家族性高乳糜微粒血症	皮下注射	Naked	PS, 2′-OMOE	Ionis Pharmaceuticals (美国)/ Akcea Therapeutics (美国)
	2020	Viltolarsen/ NS-065	杜氏肌营养不良症	静脉注射	Naked	PMO	Nippon Shinyaku (日本)
	2021	Casimersen/ Amondys45	杜氏肌营养不良症	静脉注射	Naked	PMO	Sarepta Therapeutics (美国)
	2023	Tofersen/ Qalsody	SOD1基因突变肌萎缩侧索硬化症	静脉注射	Naked	PS, 2′-OMOE	Ionis Pharmaceuticals (美国)/ Biogen (美国)
	2023	Eplontersen/ Wainua	转甲状腺素蛋白淀粉样变性	皮下注射	GalNAc	PS, 2′-OMOE	Ionis Pharmaceuticals (美国)/ Akcea Therapeutics (美国)
	2024	Imetelstat/ Rytelo	骨髓增生异常综合征	静脉注射	C16	NPS	Geron Corporation (美国)
	2024	Olezarsen/ Tryngolza	家族性乳糜微粒血症综合征	皮下注射	GalNAc	PS, 2′-OMOE	Ionis Pharmaceuticals (美国)
siRNA	2018	Patisiran/ Onpattro	成人遗传性转甲状腺素蛋白淀粉样变性	静脉注射	LNP	2′-OMe	Alnylam Pharmaceuticals (美国)
	2019	Givosiran/ Givlaari	成人急性肝卟啉病	皮下注射	GalNAc	PS, 2′-OMe, 2′-F	Alnylam Pharmaceuticals (美国)
	2020	Lumasiran/ Oxlumo	原发性高草酸尿症1型	皮下注射	GalNAc	PS, 2′-OMe, 2′-F	Alnylam Pharmaceuticals (美国)
	2021	Inclisiran/ Leqvio	高胆固醇血症血脂异常	皮下注射	GalNAc	PS, 2′-OMe, 2′-F	Novartis (瑞士)
	2022	Vutrisiran/ Amvuttra	成人遗传性转甲状腺素蛋白淀粉样变性	皮下注射	GalNAc	PS, 2′-OMe, 2′-F	Alnylam Pharmaceuticals (美国)
	2023	Nedosiran/ Rivfloza	原发性高草酸尿症1型	皮下注射	GalNAc	PS, 2′-OMe, 2′-F	Dicerna Pharmaceuticals (美国)
	2025	Fitusiran/ Qfitlia	A型或B型血友病	皮下注射	GalNAc	PS, 2′-OMe, 2′-F	Sanofi (法国)/ Alnylam Pharmaceuticals (美国)
mRNA	2021	Tozinameran/ Comirnaty	新型冠状病毒感染	肌肉注射	LNP	m1Ψ	BioNTech (德国)/Pfizer(美国)
	2020	Elasomeran/ SpikeVax	新型冠状病毒感染	肌肉注射	LNP	m1Ψ	Moderna Therapeutics (美国)
	2023	SYS6006/ 度恩泰	新型冠状病毒感染	肌肉注射	LNP	m1Ψ	石药集团(中国)
	2024	mRNA-1345/ mRESVIA	呼吸道合胞病毒感染	肌肉注射	LNP	m1Ψ	Moderna Therapeutics (美国)
适配体	2004	Pegaptanib/ Macugen	年龄相关性黄斑变性	眼内注射	PEG缀合	2′-OMe, 2′-F	Eyetech Pharmaceuticals (美国)
适配体	2023	Avacincaptad Pegol/Izervay	年龄相关性黄斑变性引起的地理萎缩	眼内注射	PEG缀合	2′-OMe, 2′-F	Astellas Pharma (日本)

Table 1

Fig. 1

Table 2

Fig. 2

Fig. 3

Fig. 4

Table 3

Fig. 5

Table 4

Table 5

Fig. 6

References 95

[1]	Sun XY, Setrerrahmane S, Li CC, Hu JL, Xu HM. Nucleic acid drugs: recent progress and future perspectives. Signal Transduct Target Ther, 2024, 9(1): 316. pmid: 39609384
[2]	Hu B, Zhong LP, Weng YH, Peng L, Huang YY, Zhao YX, Liang XJ. Therapeutic siRNA: state of the art. Signal Transduct Target Ther, 2020, 5(1): 101. pmid: 32561705
[3]	Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater, 2023, 35(51): e2303261. pmid: 37196221
[4]	Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: an overview and prospectus. Nat Rev Drug Discov, 2021, 20(6): 427-453. pmid: 33762737
[5]	Santarpia G, Carnes E. Therapeutic applications of aptamers. Int J Mol Sci, 2024, 25(12): 6742. pmid: 38928448
[6]	Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol, 2017, 35(3): 222-229. pmid: 28244992
[7]	Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther, 2012, 20(3): 513-524. pmid: 22252451
[8]	Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell A 3rd, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang XH, Seth PP, Crooke ST. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol, 2019, 37(6): 640-650. pmid: 31036929
[9]	Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol, 2017, 35(3): 238-248. pmid: 28244990
[10]	Springer AD, Dowdy SF. GalNAc-siRNA conjugates:leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther, 2018, 28(3): 109-118. pmid: 29792572
[11]	Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng WP, Zhou HH, Han S, Ivarsson M, Miller J, Zaks T. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med, 2021, 384(5): 403-416. pmid: 33378609
[12]	Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med, 2020, 383(27): 2603-2615. pmid: 33301246
[13]	Goswami J, Cardona JF, Hsu DC, Simorellis AK, Wilson L, Dhar R, Tomassini JE, Wang XW, Kapoor A, Collins A, Righi V, Lan L, Du JJ, Zhou HH, Stoszek SK, Shaw CA, Reuter C, Wilson E, Miller JM, Das R, study investigators. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Lancet Infect Dis, 2024, 25(4): 411-423. pmid: 39608389
[14]	Albertsen CH, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev, 2022, 188: 114416. pmid: 35787388
[15]	Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev, 2020, 154-155: 37-63. pmid: 32526452
[16]	Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discov, 2024, 23(4): 281-300. pmid: 38263456
[17]	Jiang ZW, Thayumanavan S. Non-cationic material design for nucleic acid delivery. Adv Ther (Weinh), 2020, 3(3): 1900206. pmid: 34164572
[18]	Wang CR, Zhao CY, Wang WP, Liu XQ, Deng HZ. Biomimetic noncationic lipid nanoparticles for mRNA delivery. Proc Natl Acad Sci USA, 2023, 120(51): e2311276120. pmid: 38079547
[19]	Gissot A, Camplo M, Grinstaff MW, Barthélémy P. Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids. Org Biomol Chem, 2008, 6(8): 1324-1333. pmid: 18385837
[20]	Zhou XY, Wang SH, Zhu YJ, Pan YF, Zhang LH, Yang ZJ. Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: the use of nucleolipids. Med Res Rev, 2020, 40(4): 1178-1199. pmid: 31820472
[21]	Moreau L, Barthélémy P, Li YG, Luo D, Prata CAH, Grinstaff MW. Nucleoside phosphocholine amphiphile for in vitro DNA transfection. Mol Biosyst, 2005, 1(3): 260-264. pmid: 16880990
[22]	Chabaud P, Camplo M, Payet D, Serin G, Moreau L, Barthélémy P, Grinstaff MW. Cationic nucleoside lipids for gene delivery. Bioconjug Chem, 2006, 17(2): 466-472. pmid: 16536479
[23]	Luvino D, Khiati S, Oumzil K, Rocchi P, Camplo M, Barthélémy P. Efficient delivery of therapeutic small nucleic acids to prostate cancer cells using ketal nucleoside lipid nanoparticles. J Control Release, 2013, 172(3): 954-961. pmid: 24041711
[24]	Tonelli G, Oumzil K, Nallet F, Gaillard C, Navailles L, Barthélémy P. Amino acid-nucleotide-lipids: effect of amino acid on the self-assembly properties. Langmuir, 2013, 29(18): 5547-5555. pmid: 23565776
[25]	Montis C, Milani S, Berti D, Baglioni P. Complexes of nucleolipid liposomes with single-stranded and double- stranded nucleic acids. J Colloid Interface Sci, 2012, 373(1): 57-68. pmid: 22138265
[26]	Cuomo F, Ceglie A, Colafemmina G, Germani R, Savelli G, Lopez F. Polyadenylic acid binding on cationic liposomes doped with the non-ionic nucleolipid lauroyl uridine. Colloids Surf B Biointerfaces, 2011, 82(2): 277-282. pmid: 20884180
[27]	Zhou XY, Pan YF, Li Z, Li HT, Wu J, Ma Y, Guan Z, Yang ZJ. siRNA packaged with neutral cytidinyl/cationic/PEG lipids for enhanced antitumor efficiency and safety in vitro and in vivo. ACS Appl Bio Mater, 2020, 3(9): 6297-6309. pmid: 35021760
[28]	Ma Y, Zhu YJ, Wang C, Pan DL, Liu S, Yang MY, Xiao ZP, Yang XT, Zhao WT, Zhou XY, Li YD, Pan YF, Sun J, Wang SH, Guan Z, Zhang LH, Yang ZJ. Annealing novel nucleobase-lipids with oligonucleotides or plasmid DNA based on H-bonding or π-π interaction: Assemblies and transfections. Biomaterials, 2018, 178: 147-157. pmid: 29933101
[29]	Ma Y, Zhao WT, Li YD, Pan YF, Wang SH, Zhu YJ, Kong LX, Guan Z, Wang JC, Zhang LH, Yang ZJ. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo. Biomaterials, 2019, 197: 182-193. pmid: 30660994
[30]	Yu XT, Yu J, Dai H, Deng CY, Sun XD, Long SJ, Jiang ZJ, Jin HY, Guan Z, Yang ZJ. Novel formulation of c-di-GMP with cytidinyl/cationic lipid reverses T cell exhaustion and activates stronger anti-tumor immunity. Theranostics, 2022, 12(15): 6723-6739. pmid: 36185614
[31]	Zhou JH, Shum KT, Burnett JC, Rossi JJ. Nanoparticle- based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals (Basel), 2013, 6(1): 85-107. pmid: 23667320
[32]	Alexander MY, Akhurst RJ. Liposome-medicated gene transfer and expression via the skin. Hum Mol Genet, 1995, 4(12): 2279-2285. pmid: 8634699
[33]	Lee TWR, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem J, 2005, 387(Pt 1): 1-15. pmid: 15656784
[34]	Remy JS, Sirlin C, Vierling P, Behr JP. Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjugate Chem, 1994, 5(6): 647-654. pmid: 7873668
[35]	Kulkarni JA, Witzigmann D, Leung J, Tam YYC, Cullis PR. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale, 2019, 11(45): 21733-21739. pmid: 31713568
[36]	Yanez Arteta M, Kjellman T, Bartesaghi S, Wallin S, Wu XQ, Kvist AJ, Dabkowska A, Székely N, Radulescu A, Bergenholtz J, Lindfors L. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc Natl Acad Sci USA, 2018, 115(15): E3351-E3360. pmid: 29588418
[37]	Sarode A, Fan YC, Byrnes AE, Hammel M, Hura GL, Fu YG, Kou P, Hu C, Hinz FI, Roberts J, Koenig SG, Nagapudi K, Hoogenraad CC, Chen T, Leung D, Yen CW. Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing. Nanoscale Adv, 2022, 4(9): 2107-2123. pmid: 36133441
[38]	Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials, 2008, 29(24-25): 3477-3496. pmid: 18499247
[39]	Schober GB, Story S, Arya DP. A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient. Sci Rep, 2024, 14(1): 2403. pmid: 38287070
[40]	Creusat G, Rinaldi AS, Weiss E, Elbaghdadi R, Remy JS, Mulherkar R, Zuber G. Proton sponge trick for pH-sensitive disassembly of polyethylenimine-based siRNA delivery systems. Bioconjugate Chem, 2010, 21(5): 994-1002. pmid: 20481503
[41]	Pan YF, Zhu YJ, Ma Y, Hong JM, Zhao WT, Gao YJ, Guan J, Ren RN, Zhang Q, Yu J, Guan Z, Yang ZJ. Design and synthesis of nucleotidyl lipids and their application in the targeted delivery of siG12D for pancreatic cancer therapy. Biomed Pharmacother, 2024, 172: 116239. pmid: 38325267
[42]	Li L, Long JR, Sang Y, Wang X, Zhou XY, Pan YF, Cao YM, Huang HY, Yang ZJ, Yang J, Wang SQ. Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid. J Control Release, 2021, 340: 114-124. pmid: 34699870
[43]	Pan YF, Guan J, Gao YJ, Zhu YJ, Li HT, Guo H, He QY, Guan Z, Yang ZJ. Modified ASO conjugates encapsulated with cytidinyl/cationic lipids exhibit more potent and longer-lasting anti-HCC effects. Mol Ther Nucleic Acids, 2023, 32: 807-821. pmid: 37251692
[44]	Semple SC, Akinc A, Chen JX, Sandhu AP, Mui BL, Cho CK, Sah DWY, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen QM, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol, 2010, 28(2): 172-176. pmid: 20081866
[45]	Crooke ST, Wang SY, Vickers TA, Shen W, Liang XH. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol, 2017, 35(3): 230-237. pmid: 28244996
[46]	Zheng Y, Guo YJ, Li YT, Wu Y, Zhang LH, Yang ZJ. A novel gemini-like cationic lipid for the efficient delivery of siRNA. New J Chem, 2014, 38(10): 4952-4962.
[47]	Yang XT, Zhu YJ, Wang C, Guan Z, Zhang LH, Yang ZJ. Alkylation of phosphorothioated thrombin binding aptamers improves the selectivity of inhibition of tumor cell proliferation upon anticoagulation. Biochim Biophys Acta, 2017, 1861(7): 1864-1869. pmid: 28389332
[48]	Zhang GP, Deng JL, Yang XT, Zhu YJ, Guan Z, Zhang LH, Yang ZJ. Selective alkylation and bioactivity of phosphorothioated nucleolin aptamer AS1411. J Chin Pharm Sci, 2017, 26(1): 23-30.
[49]	Wu J, Wang SH, Li X, Zhang Q, Yang J, Ma Y, Guan Z, Yang ZJ. Selective anti-melanoma effect of phosphothioated aptamer encapsulated by neutral cytidinyl/cationic lipids. Front Cell Dev Biol, 2021, 9: 660233. pmid: 34262898
[50]	Zhu YJ, Li X, Zhang Q, Yang XT, Sun XD, Pan Y, Yuan X, Ma Y, Xu B, Yang ZJ. Aptamer AS411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer. RSC Med Chem, 2024, 15(5): 1515-1526. pmid: 38784467
[51]	Zhou XY, Pan YF, Yu LJ, Wu J, Li Z, Li HT, Guan Z, Tang XJ, Yang ZJ. Feasibility of cRGD conjugation at 5′-antisense strand of siRNA by phosphodiester linkage extension. Mol Ther Nucleic Acids, 2021, 25: 603-612. pmid: 34589281
[52]	Ceballos C, Prata CAH, Giorgio S, Garzino F, Payet D, Barthélémy P, Grinstaff MW, Camplo M. Cationic nucleoside lipids based on a 3-nitropyrrole universal base for siRNA delivery. Bioconjug Chem, 2009, 20(2): 193-196. pmid: 19159294
[53]	Ceballos C, Khiati S, Prata CAH, Zhang XX, Giorgio S, Marsal P, Grinstaff MW, Barthélémy P, Camplo M. Cationic nucleoside lipids derived from universal bases: a rational approach for siRNA transfection. Bioconjug Chem, 2010, 21(6): 1062-1069. pmid: 20481514
[54]	Fabre AL, Colotte M, Luis A, Tuffet S, Bonnet J. An efficient method for long-term room temperature storage of RNA. Eur J Hum Genet, 2014, 22: 379-385. pmid: 23860045
[55]	Philipp J, Dabkowska A, Reiser A, Frank K, Krzysztoń R, Brummer C, Nickel B, Blanchet CE, Sudarsan A, Ibrahim M, Johansson S, Skantze P, Skantze U, Östman S, Johansson M, Henderson N, Elvevold K, Smedsrød B, Schwierz N, Lindfors L, Rädler JO. pH-dependent structural transitions in cationic ionizable lipid mesophases are critical for lipid nanoparticle function. Proc Natl Acad Sci USA, 2023, 120(50): e2310491120. pmid: 38055742
[56]	Kulkarni JA, Darjuan MM, Mercer JE, Chen S, van der Meel R, Thewalt JL, Tam YYC, Cullis PR. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano, 2018, 12: 4787-4795. pmid: 29614232
[57]	Ziller A, Nogueira SS, Hühn E, Funari SS, Brezesinski G, Hartmann H, Sahin U, Haas H, Langguth P. Incorporation of mRNA in lamellar lipid matrices for parenteral administration. Mol Pharm, 2018, 15(2): 642-651. pmid: 29232147
[58]	Trollmann MFW, Böckmann RA. mRNA lipid nanoparticle phase transition. Biophys J, 2022, 121(20): 3927-3939. pmid: 36045573
[59]	Li MY, Jia L, Xie YB, Ma WL, Yan ZH, Liu FF, Deng J, Zhu A, Siwei X, Su W, Liu XF, Li SQ, Wang HM, Yu P, Zhu T. Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine. NPJ Vaccines, 2023, 8(1): 153. pmid: 37813912
[60]	Meyer RA, Hussmann GP, Peterson NC, Santos JL, Tuesca AD. A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery. Int J Pharm, 2022, 611: 121314. pmid: 34838950
[61]	Hajj KA, Melamed JR, Chaudhary N, Lamson NG, Ball RL, Yerneni SS, Whitehead KA. A potent branched-tail lipid nanoparticle enables multiplexed mRNA delivery and gene editing in vivo. Nano Lett, 2020, 20(7): 5167-5175. pmid: 32496069
[62]	Paloncýová M, Čechová P, Šrejber M, Kührová P, Otyepka M. Role of ionizable lipids in SARS-CoV-2 vaccines as revealed by molecular dynamics simulations: from membrane structure to interaction with mRNA fragments. J Phys Chem Lett, 2021, 12(45): 11199-11205. pmid: 34761943
[63]	Nakamura T, Sato Y, Yamada Y, Elwakil MMA, Kimura S, Younis MA, Harashima H. Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. Adv Drug Deliv Rev, 2022, 188: 114417. pmid: 35787389
[64]	Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du XY, Hope MJ, Madden TD, Mui BL, Semple SC, Tam YK, Ciufolini M, Witzigmann D, Kulkarni JA, van der Meel R, Cullis PR. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol, 2019, 14(12): 1084-1087. pmid: 31802031
[65]	Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol, 2020, 15(4): 313-320. pmid: 32251383
[66]	Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci USA, 2021, 118(52): e2109256118. pmid: 34933999
[67]	LoPresti ST, Arral ML, Chaudhary N, Whitehead KA. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J Control Release, 2022, 345: 819-831. pmid: 35346768
[68]	Kim M, Jeong M, Hur S, Cho Y, Park J, Jung H, Seo Y, Woo HA, Nam KT, Lee K, Lee H. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci Adv, 2021, 7(9): eabf4398. pmid: 33637537
[69]	Anthiya S, Öztürk SC, Yanik H, Tavukcuoglu E, Şahin A, Datta D, Charisse K, Álvarez DM, Loza MI, Calvo A, Sulheim E, Loevenich S, Klinkenberg G, Schmid R, Manoharan M, Esendağlı G, Alonso MJ. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. J Control Release, 2023, 357: 67-83. pmid: 36921725
[70]	Kim Y, Choi J, Kim EH, Park W, Jang H, Jang Y, Chi SG, Kweon DH, Lee K, Kim SH, Yang Y. Design of PD-L1-targeted lipid nanoparticles to turn on PTEN for efficient cancer therapy. Adv Sci (Weinh), 2024, 11(22): e2309917. pmid: 38520717
[71]	Zhang YF, Li SX, Zhou XY, Sun J, Fan XM, Guan Z, Zhang LH, Yang ZJ. Construction of a targeting nanoparticle of 3′,3″-bis-peptide-siRNA conjugate/mixed lipid with postinserted DSPE-PEG2000-cRGD. Mol Pharm, 2019, 16(12): 4920-4928. pmid: 31642677
[72]	Guo H, Hong JM, Zhu YJ, Gui HZ, Liu HY, Ren RN, Li Y, Shan SJ, Guan Z, Liu MZ, Yang ZJ. A Mannosylated peptidyl lipid CManDA doped into cytidinyl/cationic lipids efficiently delivers siG12Ss to lung cancer in vivo. J Control Release, 2025, 381: 113624. pmid: 40073943
[73]	Ma RP, Li YT, Wei Y, Zhou JJ, Ma JY, Zhang MK, Tu JY, Jiang JH, Xie ST, Tan WH, Liu XS. The dynamic process of mRNA delivery by lipid nanoparticles in vivo. Nano Today, 2024, 57: 102325.
[74]	Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov, 2024, 23(9): 709-722.
[75]	Chen JJ, Ye ZF, Huang CF, Qiu M, Song DH, Li YM, Xu QB. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8⁺ T cell response. Proc Natl Acad Sci USA, 2022, 119(34): e2207841119. pmid: 35969778
[76]	Tahtinen S, Tong AJ, Himmels P, Oh J, Paler-Martinez A, Kim L, Wichner S, Oei Y, McCarron MJ, Freund EC, Amir ZA, de la Cruz CC, Haley B, Blanchette C, Schartner JM, Ye WL, Yadav M, Sahin U, Delamarre L, Mellman I. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol, 2022, 23(4): 532-542. pmid: 35332327
[77]	Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyártó BZ. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience, 2021, 24(12): 103479. pmid: 34841223
[78]	Lv K, Yu ZL, Wang J, Li N, Wang AP, Xue TZ, Wang QX, Shi YQ, Han L, Qin W, Gong JQ, Song HJ, Zhang TT, Chang CY, Chen H, Zhong XJ, Ding J, Chen R, Liu ML, Zhang WG, Cen S, Dong YJ. Discovery of ketal-ester ionizable lipid nanoparticle with reduced hepatotoxicity, enhanced spleen tropism for mRNA vaccine delivery. Adv Sci (Weinh), 2024, 11(45): e2404684. pmid: 39387241
[79]	Judge A, McClintock K, Phelps JR, MacLachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther, 2006, 13(2): 328-337. pmid: 16275098
[80]	Back PI, Yu MZ, Modaresahmadi S, Hajimirzaei S, Zhang QS, Islam MR, Schwendeman AA, La-Beck NM. Immune implications of cholesterol-containing lipid nanoparticles. ACS Nano, 2024, 18(42): 28480-28501. pmid: 39388645
[81]	Ma XF, Sun J, Qiu C, Wu YF, Zheng Y, Yu MZ, Pei XW, Wei L, Niu YJ, Pang WH, Yang ZJ, Wang JC, Zhang Q. The role of disulfide-bridge on the activities of H-shape gemini-like cationic lipid based siRNA delivery. J Control Release, 2016, 235: 99-111. pmid: 27242198
[82]	Zhou ZY, Liu S, Zhang YF, Yang XT, Ma Y, Guan Z, Wu Y, Zhang LH, Yang ZJ. Reductive nanocomplex encapsulation of cRGD-siRNA conjugates for enhanced targeting to cancer cells. Inter J Nanomed, 2017, 12: 7255-7272. pmid: 29042774
[83]	Yang MY, Sun J, Wang C, Zhang YF, Zhang LH, Yang ZJ. Transfection of 3′,3″-bis-peptide-siRNA conjugate by cationic lipoplexes mixed with a neutral cytosin-1-yl-lipid. J Chin Pharm Sci, 2017, 26(10): 719-726.
[84]	Sun J, Qiu C, Diao YP, Wei W, Jin HW, Zheng Y, Wang JC, Zhang LH, Yang ZJ. Delivery pathway regulation of 3′,3′-bis-peptide-siRNA conjugate by nanocarrier architecture engineering. Mol Ther Nucleic Acids, 2018, 10: 75-90.
[85]	Gao YJ, Wang XX, Pan YF, Wang QX, Zhu YJ, Pan DL, Guan Z, Yang ZJ. Synthesis and anti-HCC activity of full 2ʹ-F/OMe-siRNA encapsulated with neutral cytidinyl/ cationic lipid. Acta Pharm Sin, 2023, 58(6): 1634-1640.
	高宇睛, 王玺贤, 潘宇飞, 汪全鑫, 朱月洁, 潘德林, 关注, 杨振军. 全2°-F/OMe-siRNA的设计合成及其新型混合脂材纳米制剂抗肝癌活性评价. 药学学报, 2023, 58(6): 1634-1640. [DOI]
[86]	Li Z, Wang XX, Zhou XY, Wang J, Guan Z, Yang ZJ. Optimization in chemical modification of single-stranded siRNA encapsulated by neutral cytidinyl/cationic lipids. Front Chem, 2022, 10: 843181. pmid: 35345539
[87]	Guan J, Pan YF, Li HT, Zhu YJ, Gao YJ, Wang J, Zhou Y, Guan Z, Yang ZJ. Activity and tissue distribution of antisense oligonucleotide CT102 encapsulated with cytidinyl/cationic lipid against hepatocellular carcinoma. Mol Pharm, 2022, 19(12): 4552-4564. pmid: 35508302
[88]	Pu Y, Guan J, He QY, Zhu YJ, Pan DL, Guan Z, Yang ZJ. Investigation on efficacy against hepatocellular carcinoma of novel antisense oligonucleotide targeting IGF1R mRNA encapsulated with neutral cytidinyl/cationic lipid in vitro. Acta Pharm Sin, 2024, 59(5): 1441-1448.
	蒲洋, 管静, 何仟一, 朱月洁, 潘德林, 关注, 杨振军. 靶向IGF1R mRNA的反义寡核苷酸修饰物新型制剂体外抗肝癌活性研究. 药学学报, 2024, 59(5): 1441-1448.
[89]	Zhao XR, Xu JF, Liang XX, Wang ZY, Zhu YJ, Guo DY, Wang J, Amu G, Wang Q, Yang ZJ, Tang XJ. NQO1- activatable circular antisense oligonucleotides for tumor- cell-specific survivin gene silencing and antitumor therapy. J Med Chem, 2025, 68(4): 4466-4476. pmid: 39921644
[90]	Li J, Yao PZ, Tang K, Zhao XY, Liu XY, Liu QG, Wei TX, Xuan H, Bian SQ, Guo Y, Yang ZJ, Zhang ZQ, Zhang LQ. Functional aptamers in vitro evolution for intranuclear blockage of RNA-protein interaction. J Am Chem Soc, 2024, 146(35): 24654-24662. pmid: 39167715
[91]	Ni SJ, Zhuo ZJ, Pan YF, Yu YY, Li FF, Liu J, Wang LY, Wu XQ, Li DJ, Wan YY, Zhang LH, Yang ZJ, Zhang BT, Lu AP, Zhang G. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces, 2021, 13(8): 8500-8519. pmid: 32603135
[92]	Wang SH, Zhu YJ, Wu J, Yang ZJ. Modifications and encapsulation for aptamers applications in the diseases targeting treatment and detection. Chin J Med Chem, 2019, 29(6): 456-468.
	王舒鹤, 朱月洁, 吴静, 杨振军. 核酸适配体修饰与包载及其在疾病靶向性治疗和检测中的应用. 中国药物化学杂志, 2019, 29(6): 456-468.
[93]	Sun XD, Yu XT, Zhao YQ, Xing L, Na LX, Chen Z, Xiao ZP, Dai H, Yu J, Long SJ, Wang QX, Shi XF, Guan Z, Lei M, Yang ZJ. Cyclic diguanylate analogues: Facile synthesis, STING binding mode and anti-tumor immunity delivered by cytidinyl/cationic lipid. Eur J Med Chem, 2023, 247: 115053. pmid: 36587419
[94]	Yu J, Yu XT, Sun XD, Wang QX, Long SJ, Ren RN, Guan Z, Yang ZJ. Bis-2°-F-cG^SA^SMP isomers encapsulated in cytidinyl/cationic lipids act as potent in situ autologous tumor vaccines. Mol Ther, 2024, 32(6): 1917-1933. pmid: 38637990
[95]	Xu JF, Zhao XR, Liang XX, Guo DY, Wang J, Wang Q, Tang XJ. Development of miRNA-based PROTACs targeting Lin28 for breast cancer therapy. Sci Adv, 2024, 10(38): eadp0334. pmid: 39292784

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

内容	LNP	核苷(酸)脂材
组成成分	可电离脂材/两性离子脂材/胆固醇/DSPE-PEG	核苷(酸)脂材/阳离子脂材/靶向脂材
结合力	静电相互作用	氢键/π-π堆积作用/静电相互作用
稳定性	受离子浓度影响大	多层结构稳定性高
体内分布	SORT/mRNA可用于肝、脾、肺靶向	肝、肺及胰腺肿瘤靶向
安全性	可电离脂材明显炎症反应	DNCA最大耐受量为300 mg/kg

SORT LNP	组成成分	摩尔比例	粒径(nm)	PDI	ζ-电位(mV)
mDLNP	5A2-SC8:DOPE:Cholesterol:DMG-PEG2K	15∶15∶30∶3	144.0	0.135	-3.59
肝SORT	5A2-SC8:DOPE:Cholesterol:DMG-PEG2K:DODAP	15∶15∶30∶3∶15.75	154.6	0.115	-3.82
脾SORT	5A2-SC8:DOPE:Cholesterol:DMG-PEG2K:18PA	15∶15∶30∶3∶27	167.8	0.144	-1.84
肺SORT	5A2-SC8:DOPE:Cholesterol:DMG-PEG2K:DOTAP	15∶15∶30∶3∶63	114.8	0.159	-0.89

名称	适应症	种类	临床试验号
mRNA-4157	黑色素瘤；非小细胞肺癌	mRNA肿瘤疫苗	NCT05933577 NCT06077760
mRNA-1273	带状疱疹	mRNA病毒疫苗	NCT05047770
mRNA-1647	巨细胞病毒感染	mRNA病毒疫苗	NCT05085366
mRNA-1010	季节性流感	mRNA病毒疫苗	NCT05415462
qlRV	流感	mRNA病毒疫苗	NCT05540522
NTLA-2002	遗传性血管性水肿	sgRNA和 Cas9 mRNA	NCT06634420

核酸种类	100 g脂材载药量(g)		安全性
核酸种类	LNP	核苷(酸)脂材制剂	LNP	核苷(酸)脂材制剂
siRNA	8	26	炎症反应(Dlin-MC3-DMA<1 mg/kg)； DSPE-PEG致产生抗体；胆固醇含量高(~40%)	大鼠最大耐受剂量：DNCA 300 mg/kg；CLD 15 mg/kg (未发表数据)
ASO	/	22
适配体	/	17
环二核苷酸	/	6
mRNA疫苗	5~8	22

Progress on nucleos(t)idyl lipid-based nanoparticles for nucleic acid drugs delivery

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 11

References 95

Related Articles 0

Recommended Articles

Metrics

Comments